PTC Therapeutics Inc. (NASDAQ: PTCT) is experiencing significant momentum within the biotechnology sector following a surge in its stock price to a 52-week high of $40.69. This increase reflects heightened investor confidence driven by the positive clinical outcomes of its Friedreich ataxia (FA) investigational treatment, vatiquinone. Over the past year, the company’s share value has […]
Huntington’s disease is a severe neurodegenerative disorder, characterized by its autosomal dominant inheritance pattern. This condition leads to progressive brain degeneration starting in adulthood, resulting in rapid deterioration and eventual death. The Genetic Basis and Symptoms of Huntington’s Disease The disorder is notably classified as the most prevalent among trinucleotide repeat neurodegenerative diseases. It involves […]
Teva Pharmaceutical Industries said that its US affiliate Teva Pharmaceuticals has secured approval for AUSTEDO XR (deutetrabenazine) extended-release tablets from the US Food and Drug Administration (FDA) for tardive dyskinesia (TD) and chorea associated with Huntington’s disease (HD). AUSTEDO XR is a new daily once formulation. Expected to be launched in the US later this […]